GlassScriptPhysician profile
Lea-Amber Bolduc
NPI 1336716752
$2,116.87
in general payments reported to CMS, 2019-2025
23 companies · $449 in 2025
The $449 reported for 2025 was more than what 75% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $284 · 2023: $716 · 2024: $494 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $253.50 | 2023-2025 | Wegovy |
| Amgen INC. | $241.64 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $232.62 | 2021-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.11 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $167.92 | 2021-2023 | Xarelto |
| Edwards Lifesciences Corporation | $140.71 | 2024 | Evoque |
| E.R. Squibb & Sons, L.L.C. | $124.54 | 2023 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $120.86 | 2025 | |
| Merck Sharp & Dohme LLC | $116.43 | 2021-2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $96.74 | 2022-2024 | Wainua, Farxiga |
| Kestra Medical Technology Services, INC. | $78.55 | 2024-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $77.39 | 2023 | |
| Sanofi-Aventis U.S. LLC | $44.04 | 2023 | |
| Atricure, INC. | $43.36 | 2023 | |
| Alnylam Pharmaceuticals INC. | $35.69 | 2023-2024 | Amvuttra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28.16 | 2023 | |
| Biosense Webster, INC. | $28.02 | 2023 | Carto 3 |
| Zoll Respicardia, INC. | $23.93 | 2025 | Remede System |
| Scpharmaceuticals INC. | $22.62 | 2023 | |
| Esperion Therapeutics, INC. | $17.19 | 2021 | |
| Altathera Pharmaceuticals LLC | $15.09 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $13.89 | 2024 | Arcalyst |
| Lilly USA, LLC | $12.87 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea-Amber Bolduc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.